Concepedia

Thanh Lam

TL

Statistics

Publications

13

Citations

621

H-Index

13

Active since

2003

Affiliations

University of Oxford(Current)

Arcturus Therapeutics (United States)

Oxford University Clinical Research Unit

Hospital for Tropical Diseases

Lawrence Livermore National Laboratory

Thanh Lam is an author at University of Oxford specializing in medicinal chemistry, pharmacology, and drug discovery.

ORCID

Publications per year

2003–2025

13

Publications

13

Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: Structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity

Leslie W. Tari, Michael Trzoss, Daniel C. Bensen et al. · Bioorganic & Medicinal Chemistry Letters · 2012 · 118 citations

, , +14

Tricyclic GyrB/ParE (TriBE) Inhibitors: A New Class of Broad-Spectrum Dual-Targeting Antibacterial Agents

Leslie W. Tari, Xiaoming Li, Michael Trzoss et al. · PLoS ONE · 2013 · 104 citations · Full text

, , +14

Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), Part II: Development of inhibitors with broad spectrum, Gram-negative antibacterial activity

Micheal Trzoss, Daniel C. Bensen, Xiaoming Li et al. · Bioorganic & Medicinal Chemistry Letters · 2012 · 81 citations

, , +14

Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133

Yahu A. Liu, Qihui Jin, Yefen Zou et al. · Journal of Medicinal Chemistry · 2020 · 77 citations · Full text

, , +15

Structure-based design of new DHFR-based antibacterial agents: 7-aryl-2,4-diaminoquinazolines

Xiaoming Li, M.T. Hilgers, Mark L. Cunningham et al. · Bioorganic & Medicinal Chemistry Letters · 2011 · 59 citations · Full text

, , +13

1–5 of 13